Literature DB >> 22005002

Resistance patterns and response to entecavir intensification among HIV-HBV-coinfected adults with persistent HBV viremia.

Anne F Luetkemeyer, Edwin D Charlebois, C Bradley Hare, Douglas Black, Anna Smith, Diane V Havlir, Marion G Peters.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22005002      PMCID： PMC4120944          DOI： 10.1097/QAI.0b013e3182303937

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  14 in total

1.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

Authors:  Chien-Jen Chen; Hwai-I Yang; Jun Su; Chin-Lan Jen; San-Lin You; Sheng-Nan Lu; Guan-Tarn Huang; Uchenna H Iloeje
Journal:  JAMA       Date:  2006-01-04       Impact factor: 56.272

2.  Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV.

Authors:  Karine Lacombe; Véronique Massari; Pierre-Marie Girard; Lawrence Serfaty; Joël Gozlan; Gilles Pialoux; Patrick Mialhes; Jean-Michel Molina; Caroline Lascoux-Combe; Dominique Wendum; Fabrice Carrat; Fabien Zoulim
Journal:  AIDS       Date:  2006-02-14       Impact factor: 4.177

Review 3.  EASL Clinical Practice Guidelines: management of chronic hepatitis B.

Authors: 
Journal:  J Hepatol       Date:  2008-10-29       Impact factor: 25.083

4.  Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir.

Authors:  Marcelle Bottecchia; Antonio Madejón; Julie Sheldon; Javier García-Samaniego; Pablo Barreiro; Vincent Soriano
Journal:  J Antimicrob Chemother       Date:  2008-05-08       Impact factor: 5.790

5.  Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients.

Authors:  Libuše Ratcliffe; Michael B J Beadsworth; Ashley Pennell; Matthew Phillips; Francisco J Vilar
Journal:  AIDS       Date:  2011-05-15       Impact factor: 4.177

6.  Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.

Authors:  Y Benhamou; M Bochet; V Thibault; V Di Martino; E Caumes; F Bricaire; P Opolon; C Katlama; T Poynard
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

7.  Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine.

Authors:  Vito Di Marco; Alfredo Marzano; Pietro Lampertico; Pietro Andreone; Teresa Santantonio; Piero Luigi Almasio; Mario Rizzetto; Antonio Craxì
Journal:  Hepatology       Date:  2004-10       Impact factor: 17.425

8.  Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.

Authors:  Uchenna H Iloeje; Hwai-I Yang; Jun Su; Chin-Lan Jen; San-Lin You; Chien-Jen Chen
Journal:  Gastroenterology       Date:  2006-03       Impact factor: 22.682

9.  Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.

Authors:  Samad Amini-Bavil-Olyaee; Julie Sheldon; Thomas Lutz; Christian Trautwein; Frank Tacke
Journal:  AIDS       Date:  2009-01-14       Impact factor: 4.177

10.  Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Authors:  Yun-Fan Liaw; Joseph J Y Sung; Wan Cheng Chow; Geoffrey Farrell; Cha-Ze Lee; Hon Yuen; Tawesak Tanwandee; Qi-Min Tao; Kelly Shue; Oliver N Keene; Jonathan S Dixon; D Fraser Gray; Jan Sabbat
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.